DCPH Profile
Deciphera Pharmaceuticals Inc (DCPH) is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative drugs for the treatment of cancer. The company's lead product candidate, Qinlock (ripretinib), is an oral kinase inhibitor that is approved by the US Food and Drug Administration (FDA) for the treatment of advanced gastrointestinal stromal tumors (GIST).
Here are some key highlights of Deciphera Pharmaceuticals Inc:
The company's mission is to improve the lives of patients with cancer by discovering and developing innovative therapies that target the underlying genetic and molecular drivers of the disease.
Deciphera Pharmaceuticals Inc has a deep understanding of kinase biology and has developed a proprietary platform for the discovery and development of kinase inhibitors.
Qinlock is the first FDA-approved drug that targets the specific genetic mutation that drives most cases of GIST, a rare and often difficult-to-treat cancer.
The company has a robust pipeline of other potential kinase inhibitors for the treatment of various types of cancer, including DCC-3116 for the treatment of advanced solid tumors and DCC-3014 for the treatment of hematologic malignancies.
Deciphera Pharmaceuticals Inc has partnerships with leading pharmaceutical companies and research institutions worldwide, which allows it to leverage their expertise and expand its product offerings.
As of February 18, 2023, Deciphera Pharmaceuticals Inc was listed on the NASDAQ stock exchange under the symbol DCPH, with a market capitalization of approximately $2.2 billion. The company's focus on innovative therapies for the treatment of cancer may make it an attractive investment opportunity for investors looking to support companies that are making a difference in the fight against cancer.
|
